Future Pharmacological Therapies of Portal Hypertension.

ABSTRACT:

Purpose of review

To provide an overview of recent pharmacological treatments for portal hypertension evaluated in early clinical trials, with particular emphasis on the pathophysiological basis of their use.

Recent findings

In patients with compensated cirrhosis, even small decreases in portal pressure (as small as 1 mmHg) are associated with a lower probability of decompensation. In patients with decompensated cirrhosis, portal pressure "response" to non-selective beta-blocker (NSBB) therapy is associated with a lower mortality. When present, significant portal hypertension persists even after elimination of the etiology of cirrhosis and this justifies the continued development of new drugs that target portal hypertension.

Summary

Over several decades we have gained

SUBMITTER: Ortiz GA 

PROVIDER: S-EPMC9205466 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature